New Market Report Now Available: Generics Analysis: Key Patent Case Reviews

Recently published research from Datamonitor, "Generics Analysis: Key Patent Case Reviews", is now available at Fast Market Research

by Bill Thompson

(WireNews+Co) - Boston, MA - 26 October 2012

Providing clarity regarding generic launch timing that will shape the market around Eli Lilly's antidepressant Cymbalta and Celgene's oncology drug Revlimid.

Scope
- Detailed analysis of the likely date of generic entry for Cymbalta and Revlimid
- Analysis of both products' position in their companies total prescription pharma portfolio

Highlights

Celgene is heavily dependent upon the performance of Revlimid (lenalidomide). The product generated $3.2bn in 2011, or 68.3% of the company's total sales.

The only generic version submitted so far in the US is from Natco and partner Watson. A 30-month stay runs until December 2013 and the companies have been sued for infringement of 14 patents covering Revlimid, which expire across 2016-27.

View Full Report Details (http://www.fastmr.com/prod/464838_generics_analysis_key_patent_case_reviews.aspx) (http://www.fastmr.com/prod/464838_generics_analysis_key_patent_case_reviews.aspx)

In 2012 and 2013, Cymbalta is forecast to account for 17.5% of Eli Lilly's total five major EU market sales. As such, generic launch timing will have a significant impact.

Reasons to Get this Report
- Gain clarity on when Cymbalta and Revlimid are likely to face generic competition
- Assess the threat to Eli Lilly and Celgene of these products' genericization

Report Table of Contents:

GENERIC ENTRY TIMING REVIEWS

- Key findings
- Cymbalta (duloxetine; Eli Lilly)

- EU launch of generic Cymbalta from August 2014

- Revlimid (lenalidomide; Celgene)

- Natco sued for infringement of 14 patents

APPENDIX

- References
- Exchange rates

TABLES

- Table: Cymbalta: patent protection and exclusivity in Europe
- Table: Revlimid: patent protection and exclusivity in the US
- Table: Exchange rates, 2012

FIGURES

- Figure: Cymbalta/Xeristar and Eli Lilly total five major EU market sales, 2002-17
- Figure: Revlimid and total Celgene sales, 2002-17
- Figure: US patent and exclusivity timeline relating to Revlimid
- Figure: Chemical structure of lenalidomide

Fast Market Research (http://www.fastmr.com) is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.